Treatment of lamivudine-resistant hepatitis B infection in post-renal transplant patients with Adefovir dipivoxil: preliminary results

Simple item page
dc.contributor.authorde Silva, H.J.en_US
dc.contributor.authorDassanayake, A.S.en_US
dc.contributor.authorManamperi, A.en_US
dc.contributor.authorde Silva, A.P.en_US
dc.creator.corporateauthorTransplantation Societyen_US
dc.date.accessioned2014-10-29T09:24:11Z
dc.date.available2014-10-29T09:24:11Z
dc.date.issued2006en_US
dc.descriptionIndexed in MEDLINE
dc.description.abstractWe report the treatment outcome in six post-renal transplant patients with lamivudine-resistant hepatitis B virus (LR-HBV) infection using adefovir dipivoxil and followed for 6 to 18 months. Posttransplant immunosuppressive therapy was not altered. Adefovir dipivoxil effectively suppressed hepatitis B virus DNA and improved alanine transferase, although DNA suppression seemed dependent on continued therapy. Nephrotoxicity led to withdrawal of the drug in three patients. This may limit therapeutic usefulness in a significant proportion of post-renal transplant patients with LR-HBV infection.en_US
dc.identifier.citationTransplantation Proceedings. 2006; 38(9): 3118-120en_US
dc.identifier.departmentMedicineen_US
dc.identifier.departmentPharmacologyen_US
dc.identifier.departmentMMUen_US
dc.identifier.issn0041-1345 (Print)en_US
dc.identifier.issn1873-2623 (Electronic)en_US
dc.identifier.urihttp://repository.kln.ac.lk/handle/123456789/1711
dc.publisherElsevieren_US
dc.titleTreatment of lamivudine-resistant hepatitis B infection in post-renal transplant patients with Adefovir dipivoxil: preliminary resultsen_US
dc.typeArticleen_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Journal/Magazine Articles